OpenBiome FMT product FMP250 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05333471 (ClinicalTrials.gov) | August 8, 2022 | 15/4/2022 | Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | Chronic Granulomatous Disease-associated Colitis | Drug: OpenBiome FMT product FMP250 | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Recruiting | 10 Years | 60 Years | All | 20 | Phase 1/Phase 2 | United States |